万邦医药 (301520.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 7.18B

MomentumView details →

1D Return

+8.36%

YTD Return

+40.10%

RSI (14)

42.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 7.18B

RSI (14)

42.9

MomentumView details →

1D Return

+8.36%

YTD Return

+40.10%

ProfitabilityView details →

Gross Margin

22.77%

Net Margin

10.41%

EBITDA Margin

26.22%

ROE (TTM)

1.60%

ROA (TTM)

1.52%

Asset Turnover

0.15x

GrowthView details →

Revenue YoY

−35.09%

EPS YoY

−64.27%

FCF YoY

—

Revenue CAGR 3Y

+1.68%

EPS CAGR 3Y

−34.64%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

20.60x

Quick Ratio

20.58x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

233.67M

Net Income (TTM)

24.32M

Op. CF (TTM)

4.57M

Latest newsMore news →

Wanbang Pharmaceutical announced its H1 2026 results: revenue of 87.7577 million yuan, down 40.24% year-on-year; net profit attributable to shareholders of 138,000 yuan, down 99.49% year-on-year; non-recurring net loss of 13.4309 million yuan, turning from profit to loss.8d ago

Shenzhen Stock Exchange took self-regulatory measures against 173 abnormal securities trading behaviors from July 13 to July 17, 2026, including intraday price manipulation and false orders, and conducted key monitoring on Wanbang Pharmaceutical for severe abnormal stock price fluctuations.50d ago

Similar companies

实朴检测301228.SZ 西测测试301306.SZ 中汽股份301215.SZ 苏试试验300416.SZ 矩阵股份301365.SZ 尤安设计300983.SZ

Latest newsMore news →

Wanbang Pharmaceutical announced its H1 2026 results: revenue of 87.7577 million yuan, down 40.24% year-on-year; net profit attributable to shareholders of 138,000 yuan, down 99.49% year-on-year; non-recurring net loss of 13.4309 million yuan, turning from profit to loss.8d ago Shenzhen Stock Exchange took self-regulatory measures against 173 abnormal securities trading behaviors from July 13 to July 17, 2026, including intraday price manipulation and false orders, and conducted key monitoring on Wanbang Pharmaceutical for severe abnormal stock price fluctuations.50d ago